Geode Capital Management
IGC icon

Geode Capital Management’s IGC Pharma IGC Stock Holding History

Geode Capital Management’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Sell
879,394
-163,990
-16% -$48.5K ﹤0.01% 3850
2026
Q1 		$274K Buy
1,043,384
+182,907
+21% +$50.8K ﹤0.01% 3811
2025
Q4 		$242K Buy
860,477
+8,033
+0.9% +$2.86K ﹤0.01% 3846
2025
Q3 		$355K Buy
852,444
+149,141
+21% +$56.7K ﹤0.01% 3733
2025
Q2 		$215K Buy
703,303
+3,289
+0.5% +$988 ﹤0.01% 3848
2025
Q1 		$200K Buy
700,014
+30,329
+5% +$9.57K ﹤0.01% 3851
2024
Q4 		$225K Buy
669,685
+106,716
+19% +$39.9K ﹤0.01% 3868
2024
Q3 		$240K Buy
562,969
+133,142
+31% +$53.4K ﹤0.01% 3849
2024
Q2 		$187K Buy
429,827
+105,531
+33% +$52.5K ﹤0.01% 3937
2024
Q1 		$130K Hold
324,296
– – ﹤0.01% 4075
2023
Q4 		$90.9K Hold
324,296
– – ﹤0.01% 4216
2023
Q3 		$117K Buy
324,296
+22,156
+7% +$7.92K ﹤0.01% 4192
2023
Q2 		$94.1K Hold
302,140
– – ﹤0.01% 4356
2023
Q1 		$103K Hold
302,140
– – ﹤0.01% 4329
2022
Q4 		$96K Sell
302,140
-744
-0.2% -$303 ﹤0.01% 4415
2022
Q3 		$130K Hold
302,884
– – ﹤0.01% 4437
2022
Q2 		$160K Buy
302,884
+10,395
+4% +$6.56K ﹤0.01% 4386
2022
Q1 		$277K Hold
292,489
– – ﹤0.01% 4216
2021
Q4 		$285K Hold
292,489
– – ﹤0.01% 4315
2021
Q3 		$432K Buy
292,489
+20,484
+8% +$33.1K ﹤0.01% 4100
2021
Q2 		$446K Buy
272,005
+10,334
+4% +$15.8K ﹤0.01% 3994
2021
Q1 		$468K Hold
261,671
– – ﹤0.01% 3837
2020
Q4 		$408K Hold
261,671
– – ﹤0.01% 3653
2020
Q3 		$272K Hold
261,671
– – ﹤0.01% 3623
2020
Q2 		$156K Hold
261,671
– – ﹤0.01% 3731
2020
Q1 		$128K Hold
261,671
– – ﹤0.01% 3680
2019
Q4 		$164K Buy
261,671
+2,886
+1% +$2.36K ﹤0.01% 3863
2019
Q3 		$251K Buy
258,785
+60,177
+30% +$72.4K ﹤0.01% 3697
2019
Q2 		$325K Buy
+198,608
New +$281K ﹤0.01% 3623

Other funds holding IGC

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
LC
Lawood & Co Williamsport, Pennsylvania $148M AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management's IGC Position: Q2 2026 in Review

Geode Capital Management reduced its IGC Pharma (IGC) stake by 16% in Q2 2026, selling an estimated $48.5K and leaving 879,394 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #3850.

Geode Capital Management first reported a position in IGC in Q2 2019 and has held it in 29 quarters since. The position peaked at $468K in Q1 2021. 36 funds tracked by Wall St. Rank hold IGC as of Q2 2026.

  • Geode Capital Management held 879,394 shares of IGC Pharma worth $239K as of Q2 2026.
  • Geode Capital Management sold 163,990 IGC Pharma shares in Q2 2026, an estimated $48.5K.
  • IGC Pharma made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3850 holding.
  • Geode Capital Management first reported a position in IGC Pharma in Q2 2019 and has held it in 29 quarters since.
  • Geode Capital Management's IGC Pharma position peaked at $468K in Q1 2021.
  • 36 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.